By Chris Wack Protalix BioTherapeutics and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, said Wednesday that the U.S. Food and Drug Administration has approved Elfabrio. | May 10, 2023
A drug developed by Protalix BioTherapeutics and Chiesi Group is now FDA approved for treating Fabry disease, a rare inherited metabolic disorder. The drug, Elfabrio, is an enzyme replacement therapy.
The FDA has granted approval to Elfabrio, manufactured by Chiesi Global Rare Diseases and Protalix BioTherapeutics Inc. The drug is intended to treat Fabry disease in adults, according to the press release.“This approval is a testament to the dedication of the Protalix and Chiesi teams to deliver this much-needed new therapeutic option to patients in need. The totality of clinical data
Operator: Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2023 Financial Business Results Conference Call.